Immutep Ltd (AU:IMM) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Immutep Ltd is making strides in the battle against non-small cell lung cancer (NSCLC) by advancing its clinical candidate, eftilagimod alpha (efti), into a Phase III trial. This promising drug is being tested in combination with KEYTRUDA and chemotherapy, aiming to enhance patient outcomes in one of the largest oncology markets. With strong financial backing and a strategic collaboration with MSD, Immutep is poised to potentially establish a new standard of care for NSCLC patients.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
